Trevena

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Trevena sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials none currently recruiting 14 completed early-phase tilt top decile by trial count

Trevena: 15 sponsored US clinical trials, none currently recruiting.

Trevena sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 3 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Kidney Disease, with 1 trials.

Top-decile sponsor footprint

Trevena ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 73/100

14 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

15 total, page 1 of 1

COMPLETED Phase 3

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

NCT02815709

COMPLETED Phase 3

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

NCT02820324

COMPLETED Phase 3

A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain

NCT02656875

TERMINATED Phase 2

A Pilot Study of TRV130 for the Treatment of Fracture Pain

NCT02520297

COMPLETED Phase 1

A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males

NCT02411500

COMPLETED Phase 2

A Study of TRV130 for the Treatment of Pain After Abdominoplasty

NCT02335294

COMPLETED Phase 1

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

NCT02344303

COMPLETED Phase 1

A Safety, Tolerability, PD and PK Study in Healthy Adults

NCT02211625

COMPLETED Phase 1

A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects

NCT02169934

COMPLETED Phase 2

A Study of TRV130 for the Treatment of Pain After Bunionectomy

NCT02100748

COMPLETED Phase 2

A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

NCT01966601

COMPLETED Phase 1

Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects

NCT02083315

COMPLETED Phase 1

Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males

NCT01514578

COMPLETED Phase 1

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

NCT01444872

COMPLETED Phase 1

Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure

NCT01187836

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 4
Phase 3 3

How the Trevena early-phase archive is shaped

15 indexed studies, none listed as recruiting (0% open); 14 completed (93%).

Phase mix: 3 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Kidney Disease (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Trevena: archived-pipeline peers nationwide

Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Trevena sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share TrevenaAllakosArbor Research Collaborative for HealthArena PharmaceuticalsArrowhead Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Trevena sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Trevena sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Trevena page

15 registered trials is a research-attention snapshot, not an endorsement of Trevena or any single study.

  • None of Trevena's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Kidney Disease is the condition Trevena studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Kidney Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Trevena pipeline card: 15 registered trials from official public datasets.Report a data error.